106 related articles for article (PubMed ID: 27839788)
1. Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.
Chen Y; Zheng Y; Jiang Q; Qin F; Zhang Y; Fu L; He G
Eur J Med Chem; 2017 Feb; 127():997-1011. PubMed ID: 27839788
[TBL] [Abstract][Full Text] [Related]
2. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
[TBL] [Abstract][Full Text] [Related]
3. Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors.
Halawa AH; Eskandrani AA; Elgammal WE; Hassan SM; Hassan AH; Ebrahim HY; Mehany ABM; El-Agrody AM; Okasha RM
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717402
[TBL] [Abstract][Full Text] [Related]
4. Anti-leprosy drug Clofazimine binds to human Raf1 kinase inhibitory protein and enhances ERK phosphorylation.
Guo C; Chang T; Sun T; Wu Z; Dai Y; Yao H; Lin D
Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1062-1067. PubMed ID: 30137201
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
[TBL] [Abstract][Full Text] [Related]
7. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
[TBL] [Abstract][Full Text] [Related]
8. Multi-Target Chemometric Modelling, Fragment Analysis and Virtual Screening with ERK Inhibitors as Potential Anticancer Agents.
Halder AK; Giri AK; Cordeiro MNDS
Molecules; 2019 Oct; 24(21):. PubMed ID: 31671605
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
10. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells.
Chen Y; Wang X; Cao C; Wang X; Liang S; Peng C; Fu L; He G
Oncotarget; 2017 Nov; 8(61):104193-104205. PubMed ID: 29262632
[TBL] [Abstract][Full Text] [Related]
12. Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors.
Kulkarni MR; Mane MS; Ghosh U; Sharma R; Lad NP; Srivastava A; Kulkarni-Almeida A; Kharkar PS; Khedkar VM; Pandit SS
Eur J Med Chem; 2017 Jul; 134():366-378. PubMed ID: 28431342
[TBL] [Abstract][Full Text] [Related]
13. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
14. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
[TBL] [Abstract][Full Text] [Related]
16. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
17. Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells.
Janjusevic M; Greco S; Islam MS; Castellucci C; Ciavattini A; Toti P; Petraglia F; Ciarmela P
Fertil Steril; 2016 Nov; 106(6):1530-1538.e1. PubMed ID: 27565262
[TBL] [Abstract][Full Text] [Related]
18. Kazinol-E is a specific inhibitor of ERK that suppresses the enrichment of a breast cancer stem-like cell population.
Jung YC; Han S; Hua L; Ahn YH; Cho H; Lee CJ; Lee H; Cho YY; Ryu JH; Jeon R; Kim WY
Biochem Biophys Res Commun; 2016 Feb; 470(2):294-299. PubMed ID: 26774343
[TBL] [Abstract][Full Text] [Related]
19. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
Jiménez E; Montiel M
J Cell Physiol; 2005 Aug; 204(2):678-86. PubMed ID: 15744749
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
